Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (111-120 of 218) with videos related to

Pageof 22
Sort By:
Therapeutic Advances in Medical Oncology|March 3, 2022
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577Marieke Pape, Pauline A J Vissers, Laurens V Beerepoot, et al.
Oncology Reports|February 22, 2008
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategyThomas C Wehler, Kirsten Frerichs, Claudine Graf, et al.
Oncology Reports|September 25, 2008
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancerInes Gockel, Markus Moehler, Kirsten Frerichs, et al.
BMC Cancer|August 12, 2011
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)Stefan Heinrich, Bernhard Pestalozzi, Mickael Lesurtel, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
British Journal of Cancer|August 24, 2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupThibaud Koessler, Maria Alsina, Dirk Arnold, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2020
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary positionAntonin Levy, Anna D Wagner, Cyrus Chargari, et al.
Frontiers in Oncology|March 20, 2023
Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderlyTilman Bostel, Sati Akbaba, Daniel Wollschläger, et al.
Journal of Cancer Research and Clinical Oncology|September 19, 2014
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!Markus Moehler, Thomas Thomaidis, Chourouk Zeifri, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 28, 2022
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II TrialVisvakanth Sivanathan, Christoph Utz, Thomas Thomaidis, et al.
Pageof 22

Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
Therapeutic Advances in Medical Oncology|March 3, 2022
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577Marieke Pape, Pauline A J Vissers, Laurens V Beerepoot, et al.
Oncology Reports|February 22, 2008
PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategyThomas C Wehler, Kirsten Frerichs, Claudine Graf, et al.
Oncology Reports|September 25, 2008
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancerInes Gockel, Markus Moehler, Kirsten Frerichs, et al.
BMC Cancer|August 12, 2011
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)Stefan Heinrich, Bernhard Pestalozzi, Mickael Lesurtel, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
British Journal of Cancer|August 24, 2021
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupThibaud Koessler, Maria Alsina, Dirk Arnold, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2020
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary positionAntonin Levy, Anna D Wagner, Cyrus Chargari, et al.
Frontiers in Oncology|March 20, 2023
Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderlyTilman Bostel, Sati Akbaba, Daniel Wollschläger, et al.
Journal of Cancer Research and Clinical Oncology|September 19, 2014
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!Markus Moehler, Thomas Thomaidis, Chourouk Zeifri, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|February 28, 2022
Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II TrialVisvakanth Sivanathan, Christoph Utz, Thomas Thomaidis, et al.
Pageof 22